The DOH has earmarked P18 million for the trial of Avigan, an antiviral medication, on patients suffering from COVID-19. Read:
Earlier, the DOH said Avigan would be tested on at least 100 COVID-19 patients here and that the Japanese government would provide the Philippines with supplies of the medicine.
He said 87 people would join the clinical trials, with 12 hospitals actively recruiting participants.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
DOH allocates P18M for trial of antiviral drug Avigan — Duterte reportMANILA, Philippines — The Department of Health (DOH) allocated P18 million for the trial of antiviral medication Avigan on coronavirus disease (COVID-19) patients, President Rodrigo Duterte
Read more »
Sakay.ph now has GPS tracking for some public transport in PasigThe transit directions app is working with the Pasig City government to allow users to track buses and shuttles plying specific routes as they make their way through the city.
Read more »
PH Coast Guard hiring 100 more medical technologists for COVID-19 fightThe Philippine Coast Guard is in need of 100 medical technologists to boost its medical workforce to help in the fight against COVID-19. | FMangosingINQ
Read more »
Palace brands as ‘fake news’ Facebook geotag of PH as province of ChinaMalacañang has branded as fake news the Facebook location tag that described the Philippines as a supposed province of China.
Read more »
Number of PH health workers with coronavirus climbs to 2,314The number of health workers who tested positive for the coronavirus rose to 2,314, with majority of infections seen in nurses and physicians, the DOH announced on Monday, May 18. COVID19PH
Read more »
PH internet deal with Facebook a go by September 2020 — DICTMANILA, Philippines — The Philippine government’s massive internet deal with social media giant Facebook is pushing through after being entangled in geopolitical tensions between the United
Read more »